How Should We Determine the Role of Bezlotoxumab for Pediatric <i>Clostridioides difficile</i> Infection?-Reference-Cited by-同舟云学术

How Should We Determine the Role of Bezlotoxumab for Pediatric Clostridioides difficile Infection?

Published:2023-04-21 Issue:6 Volume:12 Page:332-333
ISSN:2048-7207
Container-title:Journal of the Pediatric Infectious Diseases Society
language:en
Short-container-title:

Author:

Sandora Thomas J¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Boston Children’s Hospital, Harvard Medical School , Boston, Massachusetts , USA

Abstract

The newly published MODIFY III trial established a safe pediatric dose of bezlotoxumab but did not conclusively demonstrate efficacy in decreasing the rate of recurrence of Clostridioides difficile infection in children. This editorial addresses considerations for bezlotoxumab use in pediatrics.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,General Medicine,Pediatrics, Perinatology and Child Health

Link

https://academic.oup.com/jpids/advance-article-pdf/doi/10.1093/jpids/piad025/50060369/piad025.pdf

Reference10 articles.

1. Clostridioides difficile infection in children: research progress, pitfalls, and priorities;Kociolek;J Pediatric Infect Dis Soc,2021

2. Bezlotoxumab for prevention of recurrent Clostridium difficile infection;Wilcox;N Engl J Med,2017

3. Real-world experience of bezlotoxumab for prevention of Clostridioides difficile infection: a retrospective multicenter cohort study;Hengel;Open Forum Infect Dis,2020

4. The role of bezlotoxumab for the prevention of recurrent Clostridioides difficile infections: a review of the current literature and paradigm shift after 2021;Hyte;Antibiotics (Basel),2022

5. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults;Johnson;Clin Infect Dis,2021